ABSTRACT
Experiments on F1(CBA×C57BL/6) mice with experimental metastatic melanoma B16 F10 showed that single intravenous injection of xenogeneic bone marrow mesenchymal stromal cells (BM-MSC) in a dose of 106 cells/mouse significantly increased 100-day survival rate of tumor-bearing animals. In contrast, administration of BM-MSC in a dose of 2×106 cells/ mouse reduced survival rates in comparison with the biocontrol (injection of B16 cells alone, 5×105 cells/mouse). This phenomenon can be related to in vivo participation of BM-MSC in reprogramming of resident tissue macrophages, including tumor microenvironment, towards pro- (M1) or anti-inflammatory (M2) phenotype. This is indirectly confirmed by the data on switching from activation to inhibition of ROS-producing activity of blood mononuclears and peritoneal macrophages in tumor-bearing mice in the test of luminol-dependent zymosaninduced chemiluminescence.
Subject(s)
Lung Neoplasms/therapy , Macrophages/immunology , Melanoma, Experimental/therapy , Mesenchymal Stem Cell Transplantation/methods , Mesenchymal Stem Cells/immunology , Skin Neoplasms/therapy , Administration, Intravenous , Animals , Cell Count , Cellular Reprogramming/genetics , Cellular Reprogramming/immunology , Female , Humans , Lung Neoplasms/immunology , Lung Neoplasms/mortality , Lung Neoplasms/secondary , Macrophages/pathology , Male , Melanoma, Experimental/immunology , Melanoma, Experimental/mortality , Melanoma, Experimental/secondary , Mesenchymal Stem Cells/cytology , Mice , Mice, Inbred C57BL , Mice, Inbred CBA , Reactive Oxygen Species/immunology , Reactive Oxygen Species/metabolism , Skin Neoplasms/immunology , Skin Neoplasms/mortality , Skin Neoplasms/pathology , Survival Analysis , Transplantation, Heterologous , Tumor Microenvironment/genetics , Tumor Microenvironment/immunologyABSTRACT
Rats with sarcoma M-1 were exposed to high dose rate irradiation with 169Yb source. In 25 days after introduction of a trocar with sealed capsule with 169Yb source into the tumor, complete tumor regression was observed in 70% animals. The results suggest feasibility of using 169Yb source for high-dose rate brachytherapy and development of the personalized medicine approaches.
Subject(s)
Brachytherapy/methods , Sarcoma, Experimental/radiotherapy , Ytterbium/therapeutic use , Animals , Area Under Curve , Male , RatsABSTRACT
On November 23, 2015 in Protvino of the Moscow Region there was begun proton therapy using Russia's first medical therapeutic complex "Prometheus" produced by JSC "PRO- TOM" and certified to treat patients with head and neck tumors. The complex allows irradiating patients with active scanning beam. Energy of beam is 30-250MeV and maximum field size is 10 cm vertically and 40 cm horizontally. The manufacturer declared parameters were confirmed during preclinical stud- ies. By April 8, 2016 the successful proton therapy received 20 patients with complex "targets" mostly located, from the point of view of radiation tolerance, near the critical structures.
Subject(s)
Head and Neck Neoplasms/radiotherapy , Proton Therapy , Humans , Proton Therapy/instrumentation , Proton Therapy/methods , Proton Therapy/trends , RussiaABSTRACT
We studied the effect of T1023, NO-synthase inhibitor, N-acyl-S-alkyl-isothiourea in a single administration at a dose of 75 mg/kg on the growth of transplantable rat sarcoma M-1 and the development of acute skin reactions after the local impact of γ-radiation at the doses of 32 and 36 Gy. The results showed that the T1023 at a single dose had no effect on the growth of sarcoma, and did not modify the radiosensitivity of the tumor and anti-tumor efficacy of γ-rays. However, at both doses T1023 significantly reduced the severity of acute radiation skin reactions. NOS inhibitor did not change the duration of the inflammatory and regenerative processes, but significantly limited the degree of radiation alteration of the deep layers of the skin and underlying tissues. The findings suggest that the hypoxic mechanism of antitumor action allows T1023 to selectively protect the non-malignant tissue during radiation therapy of solid tumors. Therefore, this compound may be regarded as a promising basis for the development of pharmacological prevention of radiotherapy complications.
Subject(s)
Enzyme Inhibitors/administration & dosage , Radiation-Protective Agents/administration & dosage , Sarcoma/drug therapy , Animals , Enzyme Inhibitors/chemical synthesis , Gamma Rays , Humans , Male , Nitric Oxide Synthase/antagonists & inhibitors , Radiation Tolerance/drug effects , Radiation-Protective Agents/chemical synthesis , Rats , Sarcoma/pathology , Sarcoma/radiotherapy , Skin/pathology , Skin/radiation effectsABSTRACT
The study was carried out using compact neutron generators with a sealed tube operating in pulsed (neutron generator ING-031) and continuous (NG-14) modes. Neutron radiation was formed due to reaction T(d,n)(4)He. The average flow of 14-MeV neutrons was 6.6×10(9) ns(-1) for ING-031 and 1.2-1.6×10(10) n s(-1) for NG-14. Duration of an impulse was â¼1 ms and pulse frequency of 50 Hz. The gamma rays of (60)Со source with an average energy of 1.25 MeV were standard radiation. Biological efficacy was estimated using the clonogenic activity of mice melanoma B-16 cells. Comparison of biological effects of neutron irradiation in pulse and continuous modes showed no significant difference between them. RBE values of pulse (ING-031) and continuous (NG-14) neutron radiation were equal-in the range of 2.4-2.6. According to the clonogenic activity of melanoma B-16 cells no dose rate effect was observed within the studied range of neutrons doses and dose rates.
